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Abstract
Von Hippel-Lindau syndrome is a rare, genetically based, autosomal dominant disorder. Its course is accompanied
by the development of multiple neoplasms with the following tumours diagnosed most commonly in the central
nervous system haemangioblastoma, clear cell renal cell carcinoma, phaeochromocytomas, pancreatic islet tumours,
and endolymphatic sac tumours. Additionally, renal and pancreatic cystadenomas and epididymal cystadenomas
have been diagnosed in males and cystadenomas of the broad ligament of the uterus have been diagnosed in
females.
The following paper presents the diagnostic way in a boy with vision disorders as the first symptom. Hypertension
retinopathy and extremely elevated blood pressure were observed during ophthalmologic consultation.
Complications of arterial hypertension were confirmed by echocardiography, which diagnosed hypertension
cardiomyopathy. Hypertension retinopathy was confirmed by optical coherence tomography. Examinations
performed in the neurology, cardiology, and finally endocrinology indicated a bilateral phaeochromocytoma as the
cause of arterial hypertension. Moreover, some genetic investigations showed a mutation in the VHL ex.1 p.Y112 C
gene responsible for the hereditary form of phaeochromocytoma which confirmed von Hippel-Lindau syndrome.
After surgical treatment of phaeochromocytoma the patient needed careful management according to the
surveillance protocol for von Hippel-Lindau disease.
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Background
Von Hippel-Lindau syndrome (retinal-cerebellar angio-
matosis) is a rare, genetically based, autosomal dominant
disorder. Its course is accompanied by with the develop-
ment of multiple neoplasms with the following tumours
diagnosed most commonly in the central nervous system
haemangioblastoma, clear cell renal cell carcinoma,
phaeochromocytomas, pancreatic islet tumours and en-
dolymphatic sac tumours. Additionally renal and pancre-
atic cystadenomas and epididymal cystadenomas have
been diagnosed in males and cystadenomas of the broad
ligament of the uterus in females [1–3].
The incidence of the syndrome is estimated at ca.
1/36 000 of live births [4]. The disease is associated with a
mutation in both alleles of the vhl gene located on the
short arm of chromosome 3. Until now over 150
mutations responsible for the development of the
syndrome have been identified [5–11].
VHL disease is a hereditary cancer syndrome character-
ized by the incidence of multiple vascular tumours. The
syndrome is caused by inactivation of the von Hippel–
Lindau protein (pVHL) [6]. Loss of the functional VHL
protein results in a high level of HIF, which causes
increased production of VEGF, PDGF, and TGF- alpha.
This explains cell growth and proliferation of microvascular
vessels. HIF also contributes to overproduction of thyrosine
hydroxylase and catecholamines in phaeochromocytoma. It
is the cause of inhibition of apoptosis of neural crest cells
and development of phaeochromocytoma and paragan-
glioma [1, 6, 7]. The syndrome has been divided into 2
types depending on the risk of phaeochromocytoma
development.
The spectrum of von Hippel-Lindau syndrome includes
Chuvash polycythaemia, otherwise referred to as familial
erythrocythemia type 2. This is a rare form of the disease
not associated with tumours and its incidence is
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particularly high in the Chuvash population inhabiting the
Volga River region [1, 6].
Tumours associated with the VHL syndrome are
typically bilateral and multifocal but rarely malignant [2, 7,
12–16]. Unlike sporadic neoplasms, they affect younger
patients [14].
The first symptoms of the disease are most often related
to haemangioblastmas in the retina, cerebellum, and other
regions of the central nervous system [17]. Patients suffer
from weakness, pain in the arms and legs, back ache,
headaches, numbness, and dizziness. Polycythaemia caused
by overproduction of erythropoietin is usually diagnosed.
MRI is used for diagnosis of haemangioblastomas.
Patients presenting with VHL syndrome for more than
10 years should be examined with MRI once a year. Small
and asymptomatic tumours only need to be carefully ob-
served. Symptomatic tumours located in the cerebellum or
in proximity of optic nerves as well as large haemangio-
blastomas should be removed neurosurgically or treated
with the gamma knife. Haemangioblastomas and postoper-
ative morbidity are the major causes of physical disability
in VHL patients.
Retinoblastoma develops in the early foetal period and at
the age of <10 year. Majority of patients do not present any
symptoms. Retinal haemangioblastomas are diagnosed by
means of ophthalmoscopy or fluorescent angiography. The
treatment of choice involves laser photocoagulation in the
early stage of the disease. Removal of the affected eye should
be considered in tumours associated with loss of vision.
Another cause of vision defects is retinopathy connected
with arterial hypertension in the development of phaeo-
chromocytoma [18–20]. In the course of VHL syndrome,
phaeochromocytomas develop most frequently in children
and young patients. They can be located in both the
adrenal glands and paraganglia [14, 15]. The most com-
mon symptoms of phaeochromocytoma comprise drench-
ing sweats, headaches, bouts of anxiety and agitation and
palpitations, as well as skin pallor, which is frequently
regarded as a pathognomonic symptom [7, 16–25]. Ac-
cording to some authors, paroxysmal or chronic arterial
hypertension is a basic symptom of phaeochromocytomas.
Literature of the subject provides information that arterial
hypertension in children is usually chronic, unlike in
adults, who suffer from periodic episodes of hypertension
[24, 25]. Very high chronic levels of arterial tension may
result in occurrence of complications, e.g. hypertensive
cardiomyopathy or retinopathy with retinal detachment
[26]. The diagnosis of sporadic and inherent phaeochro-
mocytomas is based on biochemical and imaging analyses.
Hormonally active tumours can be detected by measure-
ment of levels of catecholamines and methoxycatechola-
mines in serum or in 24-hour urine collection (the method
of choice) [21]. High sensitivity of this method is associated
with the fact that catecholamines (adrenaline and
noradrenaline) are secreted by the tumour periodically and
their elevated levels can only be detected during episodes
when a substantial amount of the substances are secreted.
In contrast, the level of methoxycatecholamines is perman-
ently elevated due to the internal conversion of catechol-
amines to methoxycatecholamines within the tumour
[27–41]. Phaeochromocytomas in the course of VHL
syndrome are assumed to secrete primarily noradrenaline
and methoxynoradrenaline. In turn, sporadic phaeochromo-
cytomas and tumours developing in the course of MEN 2
or NF1 syndromes secrete adrenaline, noradrenaline, and
their metabolites [36, 42–44]. Laboratory tests often reveal
carbohydrate metabolism disorders, leucocytosis, and hypo-
calcaemia. The latter condition can be caused by increased
sequestration of calcium ions within the tumour which uti-
lises them while releasing catecholamines [44]. Laparoscopic
partial adrenalectomy, which usually involves glucorticoster-
oid substitution, is the method of choice in phaeochromocy-
toma treatment in the paediatric population [32].
Apart from nodular lesions, numerous cystic lesions lo-
cated in different regions can occur in VHL syndrome. Two
cases of epididymal cystadenomas as the first signs of VHL
syndrome have been reported in the literature of the subject
[34], but pancreatic and renal cystadenomas may also occur
[15, 30]. These types of lesions, compound cystadenomas in
particular, require intensive supervision, since there is prob-
ability of solid mass development with a clear cell renal cell
carcinoma component [15, 31].
In the case of diagnosis of VHL syndrome compo-
nents, genetic tests should be performed in the patient
and family members. Qualification can be based on cri-
teria specified by Massachusetts General Hospital [33].
Genetic tests should be carried out in:
1/ any individuals with two VHL-associated lesions:
HB, RCC, Pheo, endolymphatic sac tumour, epididymal
or adnexal papillary cystadenoma, pancreatic
cystadenomas, and neuroendocrine tumours.
2/ any individuals with one or more of the following:
CNS HB, Pheo or paraganglioma, endolymphatic
sac tumour, and epididymal papillary cystadenoma.
3/ any individuals with > RCC diagnosed <20 years,
bilateral or multiple RCC, in multiple pancreatic
serous cystadenoma and neuroendocrine tumour,
pancreatic cyst, and any VHL associated lesion.
Classification of VHL syndrome is showed in Fig. 1.
Case presentation
The patient - a boy aged 14 with uncomplicated perinatal
history (pregnancy 1, delivery 1, 38/39 hbd, 3400 g b.w.,
length 54 cm, Apgar score 9) underwent ophthalmic exam-
ination due to bilateral scotoma. The eye examination
showed increased intraocular pressure and regions with ret-
inal detachment, which in combination with elevated values
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of arterial hypertension (180/98 mmHg) indicated hyperten-
sive retinopathy (Fig. 2). The patient was referred to the
Department of Neurology for further diagnosis due to peri-
odic headaches and dizziness. The boy was in a relatively
good condition on admission and no signs of neurological
syndromes were revealed by physical examination; however,
increased arterial hypertension of approx. 180/135 mmHg
was diagnosed. The contrast computed tomography scan of
the head showed a fluid-dense, non-contrast enhanced 3.5 ×
2.5 × 4.0 cm area in the anterior part of the temporal lobe
with thinned lamellae of adjacent bones; the image corre-
sponded to an arachnoid cyst. One focus was located
subcortically within the right temporal lobe (1 cm) and two
foci were shown in the right and left cerebellar hemispheres
(up to 1, 4 cm). According to the neurosurgical consultation
the phenomenon needed observation. No pathological signs
were exhibited by the bilateral optical nerves in the intraco-
nic and chiasm sections. The 3, 8 × 2 cm arachnoid cyst
previously shown by CT located near the anterior pole of
the right frontal lobe was also confirmed.
Since the arterial hypertension persisted at very high
values (194/147 mmHg, 189/153 mmHg) and tachycardia
ca.120/min. occured, the patient was referred to the Depart-
ment of Paediatric Cardiology in fair-serious condition.
Echocardiographic examination showed signs of hyperten-
sive cardiomyopathy in the form of grade II mitral
regurgitation and left ventricular hypertrophy without ob-
struction of the outflow tract. The patient’s condition deteri-
orated sharply during hospitalization, and the boy presented
with severe headaches with vomiting, tongue numbness,
and paresthesia of the upper and lower left limbs. Since
CNS bleeding in the course of the hypertensive crisis was
suspected, an immediate head CT scan was performed,
which showed signs of cerebral oedema. Antihypertensive
drugs and decongestants, i.e. captopril, amlodipine, carve-
dilol, furosemide, and 20 % Mannitol 100 ml i.v., were
administered. Abdominal ultrasound examination showed a
ca. a 41 × 35 mm hypoechoic tissue lesion in the right
adrenal gland without visible vascularization in colour and
power Doppler which demonstrated no visible pathological
lesions in the left adrenal gland. The Doppler ultrasound of
the aorta and renal arteries did not show significant abnor-
malities. To confirm typical phaeochromocytoma symp-
toms, the patient’s history was taken again; it provided
information that the patient had suffered from periodic
bouts of anxiety accompanied by skin pallor and excessive
sweating. Ultrasound examination results combined with
the clinical manifestations suggested a phaeochromocytoma
in the right adrenal gland; therefore, the patient was referred
to the Department of Paediatric Endocrinology and Diabe-
tology for further diagnosis and treatment. Laboratory tests






















Fig. 1 Classification of VHL syndrome
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(3,19 mmol/l), and hypocalcaemia (8,2 mg/dl). The 4-fold
assays of catecholamine levels in blood serum showed a very
high noradrenaline content accompanied by a normal level
of adrenaline; in 24-hour urine collection, the catecholamine
and methoxycatecholamine levels were substantially ele-
vated (Table 1). In addition, the levels of neuron-specific
enolase and calcitonin were measured and thyroid ultra-
sound was performed to exclude neuroblastoma and MEN
2. The results of these examinations were normal. The im-
aging diagnostics comprised an additional abdominal CT
scan, which confirmed the presence of a ca. rl 50 × ap 40 ×
cc 52 mm nodular lesion in the right adrenal gland and a
similar but smaller ca. 24-mm-diameter lesion in the left
adrenal gland (Fig. 3).
The lesions were substantially pronounced in the arterial
phase. Additionally, a fluid-dense cystic area with a diam-
eter of ca. 15 mm was detected in the upper part of the
right kidney., Antihypertensive treatment was maintained
in the Department of Endocrinology; the patient’s clinical
condition improved and his arterial tension was satisfactor-
ily stabilized. After premedication with the Plummer solu-
tion, the patient was examined by 131 I-MIBG isotopic
scintigraphy of adrenergic receptors. Examination of the
entire body was performed after 48 and 72 h, and abdom-
inal SPECT imaging was used 72 h after intravenous
radioisotope injection. Regions exhibiting increased accu-
mulation of the tracer were visible in both adrenal glands,
but the area was larger in the right adrenal gland. After
full diagnostics and premedication, the patient received
lateral transperitoneal bilateral adrenalectomy in the
Department of Surgery.
In the right adrenal gland, histopathological examin-
ation showed a 5-cm diameter solid-cystic tumour, grey-
cherry red in section, limited to the gland.
Additionally, another solid tumour with a diameter of
1, 5 cm was localized. Otherwise, the adrenal gland was
unchanged. Microscopic image: phaeochromocytoma;
immunohistochemistry: chromogranin A (+), synaptho-
physin (+); proliferative index Ki67 3–4 %; acc.to the
PASS system: 1 pt (capsule invasion). The left adrenal
gland: a 2.7-cm diameter encapsulated tumour, grey-
cherry red in section, limited to the gland. Microscopic
image: phaeochromocytoma; Immunohistochemistry: pro-
liferative index Ki67: <2 %; acc.to the PASS system: 0 pt.
Fig. 2 Hypertensive retinopathy in optical coherence tomography in a 14-year-old boy. The odema of the macula and haemorrgage to the retina is showed
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The patient has been receiving hydrocortisone replace-
ment therapy.
Due to a suspicion of the hereditary form of phaeochro-
mocytoma in the patient, a genetic test was carried out. It
showed a mutation in the VHL ex.1 p.Y112 C gene re-
sponsible for the hereditary form of phaeochromocytoma
and confirming von Hippel-Lindau syndrome. A further
genetic test was prescribed to detect hereditary syndromes
with the phaeochromocytoma component in other family
members.
Currently, 20 months after the surgery, the patient feels
good and does not report any alarming symptoms. Mea-
surements of arterial tension and the heart rate carried
out at home show normal results. Follow-up abdominal
and thyroid ultrasonography is normal; isotopic analysis
performed 8 months after the surgery (131- I MIBG scintig-
raphy) did not reveal any regions of abnormal accumu-
lation of the tracer. The level of catecholamines and
methoxycatecholamines in the control 24-h urine col-
lection was normal (Table 1). Ophthalmic examinations
showed significant regression of the changes described
earlier. The patient’s vision has improved substantially and
there are no signs of scotoma. Follow-up MRI of the CNS
did not reveal abnormalities besides the presence of the
arachnoid cyst. The lesions detected previously may have
resulted from the developing encephalopathy. Slight
muscular hyperthrophy of the left ventricle persists.
Conclusion
Recent data from the National Health and Nutrition
Survey indicates that 10 % of children and adolescents
suffer from prehypertension and 4 % have hypertension
[41,45–46]. Pheochromocytomas occur in about 0.05 %
to 0.1 % of patients with sustained hypertension. Pheo-
chromocytoma is a rare, secondary cause of juvenile
hypertension which usually occurs since the age of
10 years. Recommendations for the early diagnosis of
hypertension in childhood involve screening for hyperten-
sion in all children over the age of 3 at every visit and
ordering laboratory evaluation, echocardiography, and
renovascular imaging for all children given a diagnosis
of hypertension [44].
Up to 20 % of pheochromocytomas are diagnosed in
children. Most of them are functional tumors, and clinical
presentation includes symptoms related to catecholamine
hypersecretion andr tumor mass effect. Increasingly, pheo-
chromocytomas are identified during presymptomatic
screening in children with genetic syndromes: multiple
endocrine neoplasia type 2, von Hippel-Lindau disease,
and the paraganglioma syndromes [36].
The case presented in this case study shows the
complexity of VHL syndrome which causes diagnostic
difficulties. The first visible sign of the disease is arterial
hypertension, which should be diagnosed by a physician
during prophylactic investigations, otherwise it may lead
to complications. The diagnosis of tumours typical of
VHL syndrome, especially in a paediatric patient, neces-
sitates more comprehensive diagnostics and application
of genetic tests in the patient and family members as
well as intensive supervision of carriers of the mutated
gene. This approach facilitates early diagnosis of tumour
lesions and frequently successful treatment thereof.
Table 1 Catecholamines and their metabolites in patients with VHL syndrome before and after surgical treatment of
phaeochromocytoma
Before surgical treatment After surgical treatment Norm ranges Units
Metanephrins in 24-hour urine collection 2.68 2,68 0,30 <1 mg/24 h
Adrenalin in 24-hour urine collection 45,6 81,7 9,0 1,3-14,5 μg/24 h
Noradrenalin in 24-hour urine collection 4047,0 3105,3 18,8 8,3-51,1 μg/24 h
Dopamin in 24-hour urine collection 643,8 448,6 75,2-433,8 μg/24 h
Adrenalin in serum 76 58 x 30,0-90,0 ng/l
Noradrenalin in serum >5000,0 >5000,0 x 165,0-460,0 ng/l
Fig. 3 Bilateral nodular lesions in the right and left adrenal glands
(phaeochromocytoma) in abdominal computed tomography
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